Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Rubin

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Medical and Pediatric Oncology|March 31, 2000
Dramatic response of adult wilms tumor to paclitaxel and cisplatinR K Ramanathan, J T Rubin, N P Ohori, et al.
Therapeutic Immunology|February 1, 1995
HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2J T Rubin, R Day, R Duquesnoy, et al.
Journal of Neurosurgery|July 1, 1988
Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrierS C Saris, S A Rosenberg, R B Friedman, et al.
Annals of Surgical Oncology|July 1, 1995
Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trialJ T Rubin, M T Lotze, D Rosenfelder, et al.
Human Gene Therapy|January 1, 1994
Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune responseM T Lotze, J T Rubin, S Carty, et al.
Cancer Gene Therapy|February 24, 2001
Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cellT Iwazawa, G Y Chau, T Mori, et al.
Cancer Research|December 1, 1992
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapyF M Marincola, D Venzon, D White, et al.
Journal of Neurosurgery|August 1, 1989
The effect of intravenous interleukin-2 on brain water contentS C Saris, N J Patronas, S A Rosenberg, et al.
The Cancer Journal From Scientific American|February 11, 1998
The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapyM T Lotze, B Hellerstedt, L Stolinski, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Medical and Pediatric Oncology|March 31, 2000
Dramatic response of adult wilms tumor to paclitaxel and cisplatinR K Ramanathan, J T Rubin, N P Ohori, et al.
Therapeutic Immunology|February 1, 1995
HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2J T Rubin, R Day, R Duquesnoy, et al.
Journal of Neurosurgery|July 1, 1988
Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrierS C Saris, S A Rosenberg, R B Friedman, et al.
Annals of Surgical Oncology|July 1, 1995
Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trialJ T Rubin, M T Lotze, D Rosenfelder, et al.
Human Gene Therapy|January 1, 1994
Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune responseM T Lotze, J T Rubin, S Carty, et al.
Cancer Gene Therapy|February 24, 2001
Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cellT Iwazawa, G Y Chau, T Mori, et al.
Cancer Research|December 1, 1992
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapyF M Marincola, D Venzon, D White, et al.
Journal of Neurosurgery|August 1, 1989
The effect of intravenous interleukin-2 on brain water contentS C Saris, N J Patronas, S A Rosenberg, et al.
The Cancer Journal From Scientific American|February 11, 1998
The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapyM T Lotze, B Hellerstedt, L Stolinski, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Pageof 3